Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07095868 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
A Phase 1 study of Selected Types of Solid Tumor, sponsored by Everest Medicines (Beijing) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 7
- Study locations
NCT07095868: Recruiting Phase 1 study of Selected Types of Solid Tumor, sponsored by Everest Medicines (Beijing) Co..
NCT07095868 is a Phase 1 study of Selected Types of Solid Tumor that is actively recruiting participants, run by Everest Medicines (Beijing) Co.. The registered enrollment target is 94 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07095868, a Phase 1 study of Selected Types of Solid Tumor, is actively recruiting participants, sponsored by Everest Medicines (Beijing) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 7
- Study locations
Study Summary
Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in patients with selected solid tumors.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Pembrolizumab
- BIOLOGICAL EVM14
Study Locations (7)
Jiangsu
- Nanjing Drum Tower Hospital - Nanjing
- The First Affiliated Hospital With Nanjing Medical University - Nanjing
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Virginia
- NEXT Oncology - Fairfax
Hunan
- Hunan Cancer Hospital - Changsha
Shanghai Municipality
- Shanghai Chest Hospital - Shanghai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2025-11-17 |
| Est. Completion | 2031-11 |
| Phase | Phase 1 |
What NCT07095868 shows while recruiting
NCT07095868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher).
The record links to 1 condition, with Selected Types of Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07095868 lists 7 locations in 6 states (Jiangsu, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT07095868 about?
NCT07095868 is a clinical study titled "Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors". Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in patients with selected solid tumors.
What is the current status of trial NCT07095868?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2025-11-17. Estimated completion is 2031-11.
What conditions does trial NCT07095868 study?
This clinical trial studies the following conditions: Selected Types of Solid Tumor.
What interventions are being tested in trial NCT07095868?
The interventions under investigation include: Pembrolizumab (COMBINATION_PRODUCT), EVM14 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07095868?
This trial is sponsored by Everest Medicines (Beijing) Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07095868 being conducted?
This trial has 7 study locations across New York, Texas, Virginia, Hunan, Jiangsu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07095868's enrollment target sits among peer trials
94 616th of 2000 higher than 1,377 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI